Open-to-Accrual Therapeutic Trials


Pediatric Oncology

 


Help us say Yes. It's time.

Protocol ID

Official Title

PI Name

Lead CRC

Disease Site

Phase

NLG-2105

A Phase I Trial of Indoximod in Combination with Temozolomide-Based Therapy for Children with Progressive Primary Brain Tumors

T. Johnson

Kimberly Gray

Primary Brain Tumors

Immune Therapy

I

NLG-2102

A Phase I/II Study of the Combination of 1-Methyl-D-Tryptophan (Indoximod) and Temozolomide for Adults Patients with Temozolomide-Refractory Primary Malignant Brain Tumors

T. Johnson

Kimberly Gray

Malignant Brain Tumors

Immune Therapy

I/II

AALL0932

Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL): A Groupwide Phase III Study

C. McDonough

Kimberly Gray

ALL

III

AEWS1031

A Phase III Randomized Trial of Adding Vincristine-topotecan-cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastatic Ewing Sarcoma

C. McDonough

Kimberly Gray

Ewing Sarcoma

III

AALL1131

A Phase III Randomized Trial for Newly Diagnosed High Risk B-Precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum

C. McDonough

Kimberly Gray

ALL

III

AAML1031

Phase III Randomized Trial for Patients with de novo AML using Bortezomib and Sorafenib (IND#114480); NSC#681239, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD

C. McDonough

Kimberly Gray

AML

III

ACNS0831

Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 years

C. McDonough

Kimberly Gray

Ependymoma

III

ANHL1131

Intergroup Trial for Children or Adolescents with B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients

C. McDonough

Kimberly Gray

B-Cell NHL or B-AL

III

AALL1231

A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL)

and T- Lymphoblastic Lymphoma (T-LLy)

C. McDonough

Kimberly Gray

T-ALL and T-Lly

III

ANBL0032

Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue

C. McDonough

Kimberly Gray

Neuroblastoma

III

AEWS1221

Randomized Phase II Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma

C. McDonough

Kimberly Gray

Newly Diagnosed Metastatic Ewing Sarcoma

II